Coloplast Valuation

Q: What is the Fair Price of COLOBC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

COLOBC (DKK826.9) is trading above our estimate of [[fair value]] (DKK801.35)

Is COLOBC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of COLOBC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: COLOBC (DKK826.9) is trading above our estimate of fair value (DKK801.35)

Significantly Below Fair Value: COLOBC is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for COLOBC?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for COLOBC. This is calculated by dividing COLOBC's market cap by their current preferred multiple.
What is COLOBC's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	DKK 190.98b

COLOBC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	8.4x
Enterprise Value/EBITDA	27.4x
PEG Ratio	3.1x

Price to Earnings Ratio vs Peers

How does COLOBC's PE Ratio compare to its peers?

The above table shows the PE ratio for COLOBC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	37.6x
CTEC ConvaTec Group	46.1x	20.7%	UK£4.7b
AMS Advanced Medical Solutions Group	29x	14.8%	UK£461.1m
TSTL Tristel	34.1x	22.3%	UK£205.6m
SN. Smith & Nephew	41.2x	21.7%	UK£8.5b
COLOBC Coloplast	38.5x	12.5%	DKK 191.0b

Price-To-Earnings vs Peers: COLOBC is expensive based on its Price-To-Earnings Ratio (38.5x) compared to the peer average (37.6x).

Price to Earnings Ratio vs Industry

How does COLOBC's PE Ratio compare vs other companies in the European Medical Equipment Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	22.2%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	22.2%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: COLOBC is expensive based on its Price-To-Earnings Ratio (38.5x) compared to the European Medical Equipment industry average (30.1x).

Price to Earnings Ratio vs Fair Ratio

What is COLOBC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COLOBC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	38.5x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate COLOBC's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COLOBC forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	n/a	DKK 895.40 0%	10.5%	DKK 1,060.00	DKK 710.00	n/a	20
Jun ’25	DKK 815.40	DKK 909.89 +11.6%	10.2%	DKK 1,060.00	DKK 710.00	n/a	19
May ’25	DKK 858.40	DKK 917.05 +6.8%	10.9%	DKK 1,060.00	DKK 700.00	n/a	19
Apr ’25	DKK 934.80	DKK 897.32 -4.0%	10.3%	DKK 1,060.00	DKK 700.00	n/a	19
Mar ’25	n/a	DKK 871.79 0%	10.1%	DKK 1,000.00	DKK 700.00	n/a	19
Feb ’25	DKK 799.10	DKK 823.74 +3.1%	9.8%	DKK 962.00	DKK 631.00	n/a	19
Jan ’25	n/a	DKK 816.56 0%	10.3%	DKK 962.00	DKK 631.00	n/a	18
Dec ’24	DKK 799.90	DKK 817.67 +2.2%	10.1%	DKK 962.00	DKK 631.00	n/a	18
Nov ’24	n/a	DKK 848.78 0%	9.2%	DKK 980.00	DKK 686.00	n/a	18
Oct ’24	n/a	DKK 865.24 0%	9.9%	DKK 1,000.00	DKK 686.00	n/a	17
Sep ’24	DKK 799.60	DKK 907.53 +13.5%	10.1%	DKK 1,070.00	DKK 720.00	n/a	15
Aug ’24	DKK 847.10	DKK 928.88 +9.7%	9.9%	DKK 1,070.00	DKK 720.00	n/a	16
Jul ’24	DKK 834.00	DKK 915.44 +9.8%	11.0%	DKK 1,070.00	DKK 690.00	n/a	16
Jun ’24	DKK 874.60	DKK 915.44 +4.7%	11.0%	DKK 1,070.00	DKK 690.00	DKK 815.40	16
May ’24	DKK 963.60	DKK 912.94 -5.3%	10.0%	DKK 1,045.00	DKK 690.00	DKK 858.40	16
Apr ’24	DKK 902.80	DKK 902.63 -0.02%	9.8%	DKK 1,045.00	DKK 690.00	DKK 934.80	16
Mar ’24	DKK 828.60	DKK 903.13 +9.0%	10.2%	DKK 1,045.00	DKK 690.00	n/a	15
Feb ’24	DKK 826.10	DKK 907.33 +9.8%	9.7%	DKK 1,045.00	DKK 690.00	DKK 799.10	15
Jan ’24	DKK 812.60	DKK 918.87 +13.1%	7.7%	DKK 1,045.00	DKK 798.00	n/a	15
Dec ’23	DKK 860.60	DKK 937.00 +8.9%	11.4%	DKK 1,224.00	DKK 798.00	DKK 799.90	14
Nov ’23	DKK 838.60	DKK 948.29 +13.1%	12.2%	DKK 1,224.00	DKK 790.00	n/a	14
Oct ’23	DKK 756.60	DKK 956.00 +26.4%	12.2%	DKK 1,224.00	DKK 798.00	n/a	13
Sep ’23	DKK 869.20	DKK 974.46 +12.1%	12.8%	DKK 1,224.00	DKK 798.00	DKK 799.60	13
Aug ’23	DKK 844.60	DKK 1,003.86 +18.9%	11.8%	DKK 1,224.00	DKK 800.00	DKK 847.10	14
Jul ’23	DKK 812.10	DKK 1,038.93 +27.9%	14.4%	DKK 1,388.00	DKK 800.00	DKK 834.00	14
Jun ’23	DKK 815.40	DKK 1,044.67 +28.1%	13.9%	DKK 1,388.00	DKK 800.00	DKK 874.60	15

Analyst Forecast: Target price is less than 20% higher than the current share price.